Povlačenje teksta

Article retraction

Izjava o povlačenju

Retraction statement

Elizabeta Topić, Dubravka Čvorišćec

Uredništvo časopisa Biochemia Medica je nedavno uočilo da su sljedeće *draft* inačice smjernica (Tablica 1.) prevedene i objavljene bez dozvole Nacionalne akademije za kliničku biokemiju (NACB, Washington, DC, USA), koja posjeduje autorska prava za navedeni materijal. Objavljeni materijal nije bio u konačnom obliku te je moguće da je došlo do izvjesnih promjena na smjernicama od trenutka njihovog objavljivanja u časopisu Biochemia Medica. Smjernice stoga ne bi trebalo koristiti kao temelj za kliničku praksu.

It was recently recognized by the Editorial board of Biochemia Medica that following draft NACB guidelines (Table 1) were unfortunately translated and published without the permission of the copyright holder—the National Academy of Clinical Biochemistry, Washington, DC. The published material was not in the final format and changes may have occurred to the guideline since the time of their publication in Biochemia Medica. Translated guidelines should not be used as a basis for clinical practice.

TABLE 1. List of NACB guidelines translations to be retracted

TABLE 1. List of NACB guidelines translations to be retracted

| Guidelines | Date of publication |
|---|--|
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Testicular cancer (Section 3A) | May 15, 2006 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Prostate Cancer (Section 3B) | December 15, 2006 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Colorectal cancer (Section 3C) | June 15, 2007 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Monoclonal gammopathies (Section 3K) | June 15, 2007 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Breast cancer (Section 3F) | December 15, 2007 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Cervical cancer (Section 3J) | February 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Ovarian cancer (Section 3E) | February 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Gastric cancer (Section 3G) | June 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Bladder cancer (Section 3H) | June 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Pancreatic cancer (Section 3I) | June 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Melanoma (Section 3L) | June 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Thyroid cancer (Section 30) | June 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Lung cancer (Section 3P) | June 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Liver cancer (Section 3D) | December 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Parathyroid adenomas and carcinomas (Section 3M) | December 15, 2008 |
| NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Neoplasms of the dispersed neuroendocrine system (Section 3N) | December 15, 2008 |
| | NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Testicular cancer (Section 3A) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Prostate Cancer (Section 3B) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Colorectal cancer (Section 3C) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Monoclonal gammopathies (Section 3K) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Breast cancer (Section 3F) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Cervical cancer (Section 3J) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Ovarian cancer (Section 3B) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Gastric cancer (Section 3G) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Bladder cancer (Section 3H) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Pancreatic cancer (Section 3I) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Melanoma (Section 3I) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Thyroid cancer (Section 3D) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Lung cancer (Section 3D) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Lung cancer (Section 3D) NACB draft guidelines: Practice guidelines and recommendations for use of tumor markers in the clinic: Lung cancer (Section 3D) |

Ispričavamo se čitateljima časopisa Biochemia Medica zbog učinjenog propusta.

Elizabeta Topić i Dubravka Čvorišćec Glavne urednice The Editorial Board apologizes to the readers of Biochemia Medica for this failure.

Elizabeta Topić and Dubravka Čvorišćec Editors-in-chief